4D Molecular Therapeutics annual capital expenditures (capex)
2019
2020
2021
2022
2023
2024
2025
4D Molecular Therapeutics Capital Expenditures (CapEx) Growth & History (FDMT)
4D Molecular Therapeutics's capital expenditures (capex) was $536,000 for fiscal 2025.
View full 4D Molecular Therapeutics company overview4D Molecular Therapeutics annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $536,000 | −$3.3M | −85.84% |
| 2024 | 2024-12-31 | $3.8M | $1.0M | +36.63% |
| 2023 | 2023-12-31 | $2.8M | −$8.8M | −75.98% |
| 2022 | 2022-12-31 | $11.5M | $2.4M | +26.63% |
| 2021 | 2021-12-31 | $9.1M | $8.1M | +811.00% |
| 2020 | 2020-12-31 | $1.0M | −$2.2M | −68.78% |
| 2019 | 2019-12-31 | $3.2M | — | — |
4D Molecular Therapeutics quarterly capital expenditures (capex)
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | $70,000 | −$879,000 | −92.62% |
| Q3 2025 | 2025-09-30 | $91,000 | −$1.7M | −94.88% |
| Q2 2025 | 2025-06-30 | $66,000 | −$283,000 | −81.09% |
| Q1 2025 | 2025-03-31 | $631,000 | −$79,000 | −11.13% |
| Q4 2024 | 2024-12-31 | $949,000 | $400,000 | +72.86% |
| Q3 2024 | 2024-09-30 | $1.8M | $1.4M | +339.01% |
| Q2 2024 | 2024-06-30 | $349,000 | −$456,000 | −56.65% |
| Q1 2024 | 2024-03-31 | $710,000 | −$302,000 | −29.84% |
| Q4 2023 | 2023-12-31 | $549,000 | −$544,000 | −49.77% |
| Q3 2023 | 2023-09-30 | $405,000 | −$1.6M | −79.38% |
| Q2 2023 | 2023-06-30 | $805,000 | −$1.3M | −61.04% |
| Q1 2023 | 2023-03-31 | $1.0M | −$5.4M | −84.22% |
| Q4 2022 | 2022-12-31 | $1.1M | −$4.0M | −78.55% |
| Q3 2022 | 2022-09-30 | $2.0M | −$671,000 | −25.46% |
| Q2 2022 | 2022-06-30 | $2.1M | $1.3M | +180.33% |
| Q1 2022 | 2022-03-31 | $6.4M | $5.8M | +898.91% |
| Q4 2021 | 2021-12-31 | $5.1M | $4.6M | +903.15% |
| Q3 2021 | 2021-09-30 | $2.6M | $2.3M | +655.01% |
| Q2 2021 | 2021-06-30 | $737,000 | $617,000 | +514.17% |
| Q1 2021 | 2021-03-31 | $642,000 | −$79,000 | −10.96% |
| Q4 2020 | 2020-12-31 | $508,000 | — | — |
| Q3 2020 | 2020-09-30 | $349,000 | — | — |
| Q2 2020 | 2020-06-30 | $120,000 | — | — |
| Q1 2020 | 2020-03-31 | $721,000 | — | — |
4D Molecular Therapeutics capital expenditures (capex) trends
Over the last five fiscal years, 4D Molecular Therapeutics's capital expenditures (capex) decreased from $1.0M to $536,000, a change of −$464,000. The latest reported quarter, Q4 2025, shows $70,000.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review 4D Molecular Therapeutics source filings ↗